Fig. 7From: In vivo immunogenicity assessment and vaccine efficacy evaluation of a chimeric tandem repeat of epitopic region of OMP31 antigen fused to interleukin 2 (IL-2) against Brucella melitensis in BALB/c miceconferred protection of immunized mice with vaccine or recombinant proteins against B. melitensis M16. Mean comparison of treatments were carried out employing Tukey’s test with significance level of 0.05. Results are shown as mean ± SD of the log10CFU of B. melitensis M16per spleen (n = 4), **P < 0.01 and ***P < 0.001Back to article page